Dexamethasone and hypertension in preterm infants
- 1 February 1992
- journal article
- research article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 151 (2) , 134-135
- https://doi.org/10.1007/bf01958959
Abstract
The magnitude and duration of the effect of dexamethasone on systolic blood pressure has been examined in 13 very preterm infants (median gestational age 25 weeks). All had chronic lung disease (CLD). To exclude any effect of CLD on blood pressure each infant acted as his or her own control. Systolic blood pressure increased in all infants (P<0.01) and remained elevated for at least 48h following cessation of therapy. The median maximum increase in blood pressure was 24 mm Hg (range 13–49 mmHg) and occurred on day 4 (median, range 2–10) of treatment. One infant developed hypertensive encephalopathy. These results demonstrate the need to monitor infants with CLD throughout steroid therapy and preferably for some days after it has ceased.Keywords
This publication has 5 references indexed in Scilit:
- Dexamethasone therapy for chronic lung disease in ventilator- and oxygen-dependent infants: A controlled trialThe Journal of Pediatrics, 1989
- A Controlled Trial of Dexamethasone in Preterm Infants at High Risk for Bronchopulmonary DysplasiaNew England Journal of Medicine, 1989
- Blood pressure in very low birth weight infants in the first 70 days of lifeThe Journal of Pediatrics, 1988
- Controlled Trial of Dexamethasone in Respirator-Dependent Infants with Bronchopulmonary DysplasiaPediatrics, 1985
- Systemic hypertension in infants withbronchopulmonary dysplasiaThe Journal of Pediatrics, 1984